Login / Signup

Could HIF-1α be a novel biomarker for the clinical course and treatment of pulmonary embolism?

Bugra KergetDursun Erol AfşinAlperen AksakalSeda AşkınÖmer Araz
Published in: Turkish journal of medical sciences (2020)
HIF-1α can be used in the PE clinical risk stratification and monitoring of PE and may also serve as a valuable early indicator in intermediate high-risk PE, for which early reperfusion therapy is important.
Keyphrases
  • pulmonary embolism
  • inferior vena cava
  • endothelial cells
  • acute myocardial infarction
  • stem cells
  • cerebral ischemia
  • replacement therapy
  • subarachnoid hemorrhage